ITRM - Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026
2025-05-13 13:44:38 ET
More on Iterum Therapeutics
- Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
- Iterum Therapeutics Non-GAAP EPS of -$0.10
- Seeking Alpha’s Quant Rating on Iterum Therapeutics
- Historical earnings data for Iterum Therapeutics
- Financial information for Iterum Therapeutics